Current guidelines by the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD) and the American Association of Clinical Endocrinology endorse SGLT2 inhibitors as a core component of T2DM management, particularly for patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease [11, 12]. This evidence concerns the gene SLC5A2 and diabetes mellitus.